[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"risk-reduction\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:risk-reduction":30},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,11,0,[8,49,80,116,140,190,218,251,284,318,343],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":21,"targetDuration":4,"studyType":24,"phases":25,"briefSummary":27,"conditions":28,"keywords":32,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100639143","digital-engagement-for-lifelong-health-100639143",false,"NCT07612852","Digital Engagement for Lifelong Health","Digital Engagement for Lifelong Prevention and Health Improvement","DELPHI","Inclusion Criteria:\n\n* Apparent good general health status, confirmed by medical history and initial self-assessment.\n* Ability to understand the study information and provide informed consent.\n* Availability and motivation to participate for the entire duration of the study (12 months).\n* Access to a smartphone compatible with the DELPHI application.\n* Willingness to wear the wearable devices for continuous monitoring of physiological parameters.\n* Basic familiarity with mobile applications or willingness to receive training on their use.\n* Signed informed consent.\n\nExclusion Criteria:\n\n* Presence of severe chronic diseases in active phase (e.g., oncological, cardiovascular, or neurological diseases).\n* Acute or unstable conditions that could compromise participation in the protocol.\n* Current pregnancy.\n* Diagnosed major cognitive or psychiatric disorders that hinder understanding of or adherence to the protocol.\n* Current use of medications that significantly affect the parameters being monitored (e.g., psychotropic drugs, beta-blockers).\n* Simultaneous participation in other clinical studies.\n* Logistical difficulties that prevent frequent interaction with the platform (e.g., lack of connection, unwillingness to attend periodic follow-ups).",true,"ALL","18 Years","65 Years",{"count":22,"type":23},200,"ESTIMATED","INTERVENTIONAL",[26],"NA","The DELPHI project (Digital Engagement for Lifelong Prevention and Health Improvement) aims to develop, implement, and validate an advanced digital platform for promoting well-being and personalized prevention of chronic non-communicable diseases in healthy adults. By integrating wearable sensors, artificial intelligence, federated learning, and the Human Digital Twin (HDT) paradigm, the DELPHI platform is designed to collect, analyze, and interpret multidimensional data in order to deliver dynamic and personalized recommendations for healthy lifestyles.\n\nThe study adopts a multicenter, randomized controlled pilot design, with a maximum duration of 12 months per participant. A total of 200 healthy adults aged 18-65 will be recruited in Southern Italy (Sicily, Campania, and Basilicata) and randomly assigned to either: (1) an experimental group using the full DELPHI platform, including personalized recommendations, adaptive content, and continuous feedback; or (2) a control group using a basic version limited to passive monitoring.\n\nAs a non-clinical primary prevention pilot study, DELPHI aims to assess the operational feasibility, usability, and acceptability of the platform in real-world settings, while also exploring preliminary signals of impact on health and lifestyle domains without confirmatory purposes. Secondary objectives include monitoring physiological indicators, adherence to the app and wearable devices, and evaluating the feasibility of implementing the platform in workplace environments.\n\nData collection will rely on wearable devices, digital questionnaires, and behavioral analysis, with strong safeguards for personal data protection in compliance with GDPR and advanced security approaches such as federated learning and encryption.\n\nSpecific subgroups, including workers from the Fondazione Don Carlo Gnocchi (FDG) as well as university staff and students, will be involved in targeted assessments related to mental well-being and distress. In addition, workers from the FDG will test a virtual reality module designed to evaluate biomechanical overload risks during manual handling activities in simulated environments. These additional physiological and virtual reality components are exploratory and non-diagnostic.\n\nOverall, DELPHI seeks to provide a solid foundation for the adoption of predictive and personalized models in digital health, contributing to the development of a sustainable and accessible prevention ecosystem, particularly in Southern Italy.",[29,30,31],"Life Style, Healthy","Risk Reduction","Health Promotion",[33,34,35],"health","digitalization","prevention","RECRUITING","2026-05-25",{"date":39,"type":40},"2026-05-29","ACTUAL",{"date":42,"type":40},"2026-05-04",{"date":44,"type":23},"2027-03-30",{"name":46,"class":47},"Istituto per la Ricerca e l'Innovazione Biomedica","OTHER",1,{"id":50,"slug":51,"hasResults":11,"nctId":52,"briefTitle":53,"officialTitle":53,"acronym":54,"eligibilityCriteria":55,"healthyVolunteers":11,"sex":18,"minAge":4,"maxAge":4,"enrollmentInfo":56,"targetDuration":4,"studyType":58,"phases":4,"briefSummary":59,"conditions":60,"keywords":66,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":48},"100563464","artificial-intelligence-for-highly-myopic-cataract-100563464","NCT06616506","Artificial Intelligence for Highly Myopic Cataract","AI-HMC","Inclusion Criteria:\n\nAxial length ≥ 26 mm and patients with high myopia complicated by cataracts who visit our hospital.\n\nPreoperative anterior segment photography and cataract severity assessment, along with fundus OCT examination, have been performed.\n\nIf surgical treatment is conducted, the postoperative follow-up period should be no less than 1 month.\n\nThere are no missing clinical data before and after the surgery.\n\nExclusion Criteria:\n\nPatients who are unable to cooperate with the required examinations for this study.",{"count":57,"type":23},500000,"OBSERVATIONAL","This study aims to establish a multi-center artificial intelligence model for the accurate calculation of intraocular lens and its clinical application in highly myopic cataract, so as to improve the accuracy of the prediction of postoperative diopter in highly myopic cataract patients.",[61,62,63,64,30,65],"Cataract","High Myopia","Myopia","Automatic Judgement","Diagnoses Disease",[67,68,69,70],"highly myopic cataract","artificial intelligence","cataract","big data","2026-05-06",{"date":73,"type":40},"2026-05-11",{"date":75,"type":40},"2016-01-01",{"date":77,"type":23},"2035-12-31",{"name":79,"class":47},"Shanghai High Myopia Study Group",{"id":81,"slug":82,"hasResults":11,"nctId":83,"briefTitle":84,"officialTitle":85,"acronym":86,"eligibilityCriteria":87,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":88,"enrollmentInfo":89,"targetDuration":91,"studyType":58,"phases":4,"briefSummary":92,"conditions":93,"keywords":97,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":106,"lastUpdatePostDateStruct":107,"startDateStruct":109,"completionDateStruct":111,"leadSponsor":113,"locationsCount":115},"100495547","exogenous-and-endogenous-risk-factors-for-early-onset-colorectal-cancer-100495547","NCT05732623","Exogenous and Endogenous Risk Factors for Early-onset Colorectal Cancer","Diet obEsity sMoking Epigenetics geneTics biomaRkers Physical Activity: An International Multicenter Case-control Study on Endogenous and Exogenous Risk Factors in Early-onset Colorectal Cancer","DEMETRA","Inclusion Criteria:\n\n* All sexes eligible\n* (for Cases) eoCRC diagnosed between 18 and 49 years and confirmed by histology (biopsy or surgical specimen in case of surgery)\n* (for Controls) negative past and present history of cancer; negative fecal occult blood test (FOBT), or negative colonoscopy.\n\nExclusion Criteria:\n\n* CRC diagnosed at ≥ 50 years\n* Diseases that can modify the dietary regimen (celiac disease, diabetes)\n* Diseases that are known to predispose to eoCRC (personal past or recent history of inflammatory bowel disease, past history of pelvic irradiation)\n* Unable to give written consents and to fill in the electronic questionnaire","49 Years",{"count":90,"type":23},2300,"10 Years","An increase in early-onset colorectal cancers (eoCRC), defined as a CRC before 50 years, is confirmed globally.\n\nCRC pathogenesis has been associated with several risk factors (family history, germline pathogenic variants, obesity, alcohol, physical activity, red meat, and a Western diet).\n\nDesign: an international, multicenter, retrospective case-control study of prospectively enrolled patients; low-risk intervention study as it will perform a fecal occult blood test Endpoint: predictive power of a semi-quantitative food frequency questionnaire (SQFFQ) developed for eoCRC.\n\nCases: Patients with a recent diagnosis of eoCRC (within 2 years from enrollment).\n\nControls: matched by age (matching range ± 5 years) and sex. Healthy volunteers will be mainly enrolled among workers within the participating hospital center. The enrolled healthy volunteers will perform a fecal occult blood test.\n\nVariables of interest: age, sex, ethnicity, BMI at the time of eoCRC diagnosis and at 18 years old, country, tobacco smoking at the time of eoCRC diagnosis and at 18 years old, sitting time, TV-viewing time, moderate-to-vigorous physical activity (MVPA), waist circumference (cm), home blood pressure levels (mmHg), fasting blood glucose (mg\u002Fdl), regular consumption of aspirin\u002FNSAID, calcium and folate supplements, oral contraceptive agents, post-menopausal hormones and years of consumptions, if the filled questionnaire reflects diet for the last 5-10 years before.\n\nCases only: date of eoCRC diagnosis, symptoms at diagnosis, eoCRC localization, eoCRC stage, histological diagnosis, type of surgery, and date (if performed), chemotherapy and radiotherapy (if performed), vital status and duration of follow-up, family history of CRC and other cancers (uterus, ovary, stomach, small intestine, urinary tract\u002Fbladder\u002Fkidney, bile ducts, brain, pancreas, skin tumors), type of germline pathogenetic variant (if performed).\n\nBefore the case-control study, three non-consecutive 24-hour Dietary Recalls (24hDRs) will validate the SQFFQ.\n\nThe SQFFQ will be administered to the validation study group during three non-consecutive calls, including one non-weekday (30-minute 24-h-recall computer-aided personal interview).\n\nPrimary Objective To measure the relative risk of specific dietary and lifestyle factors (smoking habit, alcohol intake, physical activity) for early-onset colorectal cancer in countries where eoCRC incidence is increasing versus stable\u002Fdecreasing",[94,95,96,30],"Colorectal Cancer","Early Onset Colorectal Cancer","Diet Habit",[98,99,100,101,102,103,104,105],"Early onset","Young onset","Young adult","Colon cancer","Rectal cancer","Cancer genetics","Cancer risk factors","Diet","2026-04-21",{"date":108,"type":40},"2026-04-24",{"date":110,"type":40},"2022-12-05",{"date":112,"type":23},"2035-01",{"name":114,"class":47},"San Raffaele University",8,{"id":117,"slug":118,"hasResults":11,"nctId":119,"briefTitle":120,"officialTitle":121,"acronym":4,"eligibilityCriteria":122,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":123,"targetDuration":4,"studyType":24,"phases":125,"briefSummary":127,"conditions":128,"keywords":129,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":131,"lastUpdatePostDateStruct":132,"startDateStruct":134,"completionDateStruct":136,"leadSponsor":138,"locationsCount":48},"100360327","phase-4-blood-donor-cvd-5000-100360327","NCT03971669","Blood Donor CVD 5000","Collection of Blood Samples for In-Vitro Studies From Healthy Adult Blood Donors Who Have Received Oral Typhoid Vaccine (TY21A)","Inclusion Criteria:\n\n* Age 18 years and older\n* Good general health as determined by a screening evaluation within 28 days before blood donation\n* Informed, written consent\n\nExclusion Criteria:\n\n* History of any of the following medical illnesses:\n\n  * Diabetes\n  * Cancer in past 5 years (except for basal cell carcinoma of the skin and cervical carcinoma in situ)\n  * Heart disease (Hospitalization for a heart attack, coronary artery bypass graft, arrhythmia, or syncope, within past 5 years. Current symptoms of heart disease - dyspnea, angina, orthopnea)\n  * Recurrent infections (more than 3 hospitalizations for invasive bacterial infections such as pneumonia or meningitis)\n  * Current drug or alcohol abuse\n  * Active ulcer disease or ongoing intestinal condition\n  * Treatment for anemia in last 6 months\n  * Currently being treated with anti-malarial drugs\n* Any of the following laboratory abnormalities detected during medical screening:\n\n  * WBC \\\u003C0.81 x LLN or \\> 1.09 x ULN\n  * Hemoglobin \\\u003C0.91 x LLN or \\>1.18 x ULN (women) or \\\u003C0.92 x LLN or \\>1.18 x ULN (men)\n  * Platelet count \\\u003C0.8 x LLN or \\> 1.2 x ULN\n  * (For leukopheresis or blood unit donations, the following lab values are exclusionary:\n  * WBC \\\u003C3.5 or \\>11 x 103\u002Fmm3;\n  * Hemoglobin \\\u003C12.5 or \\>18 g\u002Fdl\n  * Platelet count \\\u003C150 or \\>500 x 103\u002Fmm3)\n  * SGOT or SGPT \\>1.5 times normal\n  * Positive serology for hepatitis C or HIV antibody or hepatitis B surface antigen\n  * Positive serology for hepatitis B core antibody\n  * Poor peripheral venous access for blood donation\n  * Positive RPR\n* Other condition that in the opinion of the investigator would jeopardize the safety or rights of a volunteer participating in the trial or interfere with the scientific integrity of study.\n* Positive urine pregnancy test (HCG) on day of vaccination. Prior to each blood donation -females with menstrual history consistent with pregnancy. Pregnant women will not be enrolled, because immunological changes that occur during pregnancy may interfere with laboratory assays.",{"count":124,"type":23},150,[126],"PHASE4","This is an open-label, non-randomized study. Volunteers will be vaccinated with the typhoid oral vaccine, Vivotif. Vivotif has been licensed by the Food and Drug Administration (FDA) for travelers to developing countries. Volunteers will also be asked to provide blood, saliva, and stool specimens over a follow-up time period of up to eight years. The specimens obtained in this clinical research study will be used to further the investigator's understanding of the protective immunological mechanisms that can be elicited systemically and may be applicable to other enteric pathogens.",[30],[130],"Typhoid","2026-03-24",{"date":133,"type":40},"2026-03-27",{"date":135,"type":40},"2004-01-16",{"date":137,"type":23},"2030-06-30",{"name":139,"class":47},"University of Maryland, Baltimore",{"id":141,"slug":142,"hasResults":11,"nctId":143,"briefTitle":144,"officialTitle":145,"acronym":146,"eligibilityCriteria":147,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":148,"targetDuration":4,"studyType":24,"phases":150,"briefSummary":151,"conditions":152,"keywords":168,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":180,"lastUpdatePostDateStruct":181,"startDateStruct":183,"completionDateStruct":185,"leadSponsor":187,"locationsCount":189},"100556807","environmental-exposure-to-heavy-metals-nanoparticles-and-emergent-contaminants-and-risk-of-allergic-diseases-100556807","NCT06529913","Environmental Exposure to Heavy Metals, Nanoparticles, and Emergent Contaminants and Risk of Allergic Diseases","Model of diseAses Related to Environmental Exposure to Heavy meTals, nanopaRticles and Emergent Contaminants, Using a dIgital platfOrm of Clinical and Bio-humoral Data: the Way to Susceptibility\u002FRisK BiomArker [MATRIOSKA Study] - The Seed.","MATRIOSKA","Inclusion Criteria:\n\n* adult subjects (over 18 years of age).\n* Subjects suffering from allergic contact dermatitis due to metals.\n* Subjects with systemic allergic syndrome due to metals.\n* Adult healthy subjects.\n* Subjects able to give written informed consent.\n\nExclusion Criteria:\n\n* Subjects under the age of 18years.\n* Pregnant\u002Fbreastfeeding women.\n* Subjects suffering from chronic renal failure requiring replacement treatment.\n* Subjects suffering from other systemic pathologies related to exposure to metals.\n* Subjects suffering from gastrointestinal diseases such as celiac disease, chronic inflammatory intestinal diseases, tumors, other skin diseases.\n* Subjects unable to express written informed consent.",{"count":149,"type":23},280,[26],"The goal of this clinical trial is to collect environmental, bio-humoral, and clinical data derived from patients with allergic contact dermatitis (ACD) and systemic metal allergic syndromes related to the exposure to heavy metals, nanoparticles, and emergent contaminants and from healthy subjects.\n\nThe main question it aims to answer is: are environmental, bio-humoral, and clinical data derived from patients with ACD and systemic metal allergic syndromes, related to the exposure to heavy metals, nanoparticles, and emergent contaminants, different from ones obtained by healthy subjects? Researchers will compare serum and urine concentration of heavy metals and nanoparticles, patch test to metals, within-breath analysis of oscillometry parameters, serum zonulin, and serum levels of protein oxidation products among patients with systemic allergic syndrome (1st study group), patients with ACD (2nd study group) and healthy subjects (3rd study group).\n\nParticipants will undergo:\n\n* measurement of exposure to heavy metals and nanoparticles including nickel, cobalt, chromium, palladium, molybdenum, aluminium, and copper, through serum and urine measurement of concentration.\n* Patch test to before mentioned metals.\n* Within-breath analysis of oscillometry parameters.\n* Measurement of serum zonulin (related to gastro-intestinal exposure).\n* Measurement of serum levels of protein oxidation products (as markers of systemic oxidative stress).",[153,154,155,156,157,158,159,160,161,162,163,164,165,166,167,30],"Allergic Contact Dermatitis","Metal Allergy","Food Allergy","Nickel Sensitivity","Nickel; Eczema","Aluminum Allergy","Chromium; Eczema","Functional Gastrointestinal Disorders","Respiratory Injury","Pollution; Exposure","Pollution Related Respiratory Disorder","Environmental Exposure","Environment Related Disease","Environmental Illness","Oxidative Stress",[154,169,170,171,172,173,174,175,176,177,153,155,160,161,164,178,179],"Nanoparticles","Emergent contaminants","Nickel","Aluminium","Copper","Chromium","Cobalt","Palladium","Titanium","Patch test","Biomarkers","2026-02-23",{"date":182,"type":40},"2026-02-24",{"date":184,"type":40},"2025-01-13",{"date":186,"type":23},"2026-12-31",{"name":188,"class":47},"Fondazione Policlinico Universitario Agostino Gemelli IRCCS",2,{"id":191,"slug":192,"hasResults":11,"nctId":193,"briefTitle":194,"officialTitle":195,"acronym":4,"eligibilityCriteria":196,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":197,"targetDuration":4,"studyType":24,"phases":199,"briefSummary":200,"conditions":201,"keywords":204,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":209,"lastUpdatePostDateStruct":210,"startDateStruct":212,"completionDateStruct":214,"leadSponsor":216,"locationsCount":48},"100563684","the-impact-of-coach-guided-risk-communication-on-the-risk-of-major-depression-100563684","NCT06619366","The Impact of Coach-guided Risk Communication on the Risk of Major Depression","The Impact of Coach-guided Risk Communication on the Risk of Major Depression: A Randomized Controlled Trial","Inclusion Criteria:\n\n* no MDE at baseline, or full remission for 2 months for those who had a past MDE (see below the question).\n* Aged 18 and 65 years.\n* At high risk of MDE based on the depression risk calculators (predicted risk of 6.5%+ for males and 11.2%+ for females), which represent the top two deciles of male and female populations in Canada.\n* Agreement to be contacted for follow-up assessments, and\n* no language barriers to English or French\n\nExclusion Criteria:\n\nindividuals who\n\n* cannot provide informed consent,\n* do not agree to be followed,\n* cannot communicate in English and French, or\n* report suicide behaviors (score \\>0 on item 9 of the Patient Health Questionnaire (PHQ-9)).",{"count":198,"type":23},1000,[26],"Depression is a highly prevalent and disabling mental health problem. One way of preventing depression is to stop it before it happens through effective self-management. Working with potential users, a coach-guided, personalized depression risk communication tool (PDRC) was developed for sharing information about individualized depression risk, risk profile (risk factors present), potential risk reduction and evidence-based self-help strategies. It is anticipate that the PDRC will greatly motivate users to actively engage in self-help and help seeking, leading to a reduced risk of depression. The proposed study will recruit 500 male and 500 female adults who are at high risk of having depression across Canada, and randomly allocate them into the intervention and control groups. Participants will be followed for 12 months. The data of the trial will allow us to answer the questions: (1) Can the coach-guided PDRC reduce the risk of depression? (2) Does the intervention motivate people to actively engage in evidence-based self-help and help-seeking behaviors? (3) For whom the intervention works best? and (4) what are the costs and potential savings associated with the intervention? If successful, this project will offer a novel and effective tool for early prevention of major depression in the Canadian general population, help us understand how it works and the cost-effectiveness of implementing such a tool in the community from the economic perspective.",[202,30,203],"Major Depressive Episode","Self Efficacy",[205,206,207,208],"major depressive episode","risk communication","coach-guided","self-help","2025-08-26",{"date":211,"type":40},"2025-09-02",{"date":213,"type":40},"2025-02-10",{"date":215,"type":23},"2029-10",{"name":217,"class":47},"Dalhousie University",{"id":219,"slug":220,"hasResults":11,"nctId":221,"briefTitle":222,"officialTitle":223,"acronym":224,"eligibilityCriteria":225,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":226,"targetDuration":4,"studyType":24,"phases":228,"briefSummary":229,"conditions":230,"keywords":234,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":242,"lastUpdatePostDateStruct":243,"startDateStruct":245,"completionDateStruct":247,"leadSponsor":249,"locationsCount":48},"100461044","intravenous-vs-oral-hydration-to-reduce-the-risk-of-post-contrast-acute-kidney-injury-after-intravenous-contrast-enhanced-computed-tomography-in-patients-with-severe-chronic-kidney-disease-100461044","NCT05283512","Intravenous vs. Oral Hydration to Reduce the Risk of Post-Contrast Acute Kidney Injury After Intravenous Contrast-Enhanced Computed Tomography in Patients With Severe Chronic Kidney Disease","Intravenous vs. Oral Hydration to Reduce the Risk of Post-Contrast Acute Kidney Injury After Intravenous Contrast-Enhanced Computed Tomography in Patients With Severe Chronic Kidney Disease (ENRICH): A Randomized Controlled Trial","ENRICH","Inclusion Criteria:\n\n* eGFR \\\u003C 30 mL\u002Fmin\u002F1.73 m2\n* Scheduled for elective IV CECT\n* Age ≥ 18\n* Signed informed consent\n\nExclusion Criteria:\n\n* Allergy to Iodine\n* Pregnancy\n* Active dialysis treatment\n* Acute infectious or inflammatory disease\n* Acute pre- and\u002For post-renal kidney failure\n* Unable to understand study information",{"count":227,"type":23},254,[26],"The use of contrast media (CM) poses a risk of post-contrast acute kidney injury (PC-AKI), especially among patients chronic kidney disease (CKD). International guidelines recommend intravenous (IV) hydration with isotonic 0.9% NaCl for three-four hours pre-contrast and four-six hours post-contrast. Recent studies have proven that oral hydration or no hydration is non-inferior to IV hydration in patients with mild to moderate CKD (eGFR 30-60 mL\u002Fmin\u002F1.73 m2). However, no randomized controlled trials have evaluated alternative hydration methods against the guideline-recommended hydration protocol for the prevention of PC-AKI in high-risk patients with severe CKD (eGFR \\\u003C 30 mL\u002Fmin\u002F1.73 m2).\n\nThus, the main focus of this trial is to evaluate IV hydration vs. oral hydration for their efficacy to prevent of PC-AKI in patients with severe CKD, who are scheduled for an elective contrast-enhanced CT-scan (CECT) with IV contrast-administration.\n\nOur research hypotheses consist of the following:\n\n1. Oral hydration with bottled tap water is non-inferior to IV-hydration with isotonic 0.9% NaCl as renal prophylaxis to prevent PC-AKI in patients with severe CKD referred for an elective IV CECT.\n2. NGAL and cfDNA are early and precise plasma and urinary biomarkers of PC-AKI with excellent diagnostic and prognostic accuracy for PC-AKI, dialysis, renal adverse events, hospitalization, progression in CKD-symptoms, and all-cause mortality.",[231,232,233,30],"Contrast-induced Nephropathy","Kidney Injury","Kidney Failure, Chronic",[235,236,237,238,239,240,241],"Intravenous","Contrast material","Computed Tomography","Cardiac CT","Prophylaxis","Oral Hydration","IV-hydration","2025-07-29",{"date":244,"type":40},"2025-08-01",{"date":246,"type":40},"2022-04-20",{"date":248,"type":23},"2027-12-31",{"name":250,"class":47},"Odense University Hospital",{"id":252,"slug":253,"hasResults":11,"nctId":254,"briefTitle":255,"officialTitle":256,"acronym":257,"eligibilityCriteria":258,"healthyVolunteers":17,"sex":18,"minAge":259,"maxAge":260,"enrollmentInfo":261,"targetDuration":4,"studyType":24,"phases":262,"briefSummary":263,"conditions":264,"keywords":270,"overallStatus":274,"whyStopped":4,"lastUpdateSubmitDate":275,"lastUpdatePostDateStruct":276,"startDateStruct":278,"completionDateStruct":280,"leadSponsor":282,"locationsCount":4},"100574072","options-for-navigating-talking-about-risk-and-adolescent-choices-100574072","NCT06754527","Options for Navigating Talking About Risk and Adolescent Choices","Emotion Regulation Intervention to Prevent Substance Use Among Youth in the Child Welfare System","ON-TRAC","Inclusion Criteria:\n\n* Contact with the Rhode Island child welfare system\n* Caregiver who is a parent\u002Fguardian of a child who experienced maltreatment\n* Caregiver who speaks English or Spanish\n* Caregiver who does not have developmental delays\n* Adolescent who is between 12-15 years of age\n* Adolescent who is fluent in English\n* Adolescent who has active follow-up with the Rhode Island child welfare system due to an indicated finding of abuse or neglect in the past year\n\nExclusion Criteria:\n\n* Adolescent who cannot read at a 4th grade level\n* Adolescent who has a sibling who has participated in the program\n* Adolescent who has developmental delays\n* Adolescent who lacks parental consent for the study","12 Years","15 Years",{"count":22,"type":23},[26],"This study will examine the effectiveness of ON-TRAC (Options for Navigating Talking about Risk and Adolescent Choices), which is an online substance use prevention program that also teaches emotion regulation skills. 200 adolescents, 12-15 years of age, will be randomized to ON-TRAC or a wait list comparison group (who will be offered the intervention at the end of their study participation) to determine impact on substance use, emotion regulation abilities, mental health symptoms, and other risk behavior outcomes.",[265,266,267,268,269,30],"Substance Use (Drugs, Alcohol)","Substance Use Risk","Substance Use","Emotion Regulation","Risk Reduction Behavior",[271,272,273],"adolescent substance use","emotion regulation","risk reduction","NOT_YET_RECRUITING","2024-12-30",{"date":277,"type":40},"2025-01-01",{"date":279,"type":23},"2026-03-01",{"date":281,"type":23},"2029-02-01",{"name":283,"class":47},"Rhode Island Hospital",{"id":285,"slug":286,"hasResults":11,"nctId":287,"briefTitle":288,"officialTitle":289,"acronym":290,"eligibilityCriteria":291,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":292,"targetDuration":4,"studyType":24,"phases":294,"briefSummary":295,"conditions":296,"keywords":302,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":308,"lastUpdatePostDateStruct":309,"startDateStruct":311,"completionDateStruct":313,"leadSponsor":315,"locationsCount":317},"100563076","strong-for-surgery--strong-for-life---intensive-prehabilitation-for-risk-reduction-in-ventral-hernia-repair-100563076","NCT06611462","STRONG for Surgery & Strong for Life - Intensive Prehabilitation for Risk Reduction in Ventral Hernia Repair","Effect of Tailored, Intensive Prehabilitation for Risky Lifestyles Before Ventral Hernia Repair on Postoperative Outcomes, Health, and Costs - a Randomised Controlled Trial (STRONG-Hernia)","STRONG-Hernia","Inclusion Criteria:\n\n* Participants ≥18 years scheduled for ventral hernia repair (defect smaller than 8cm)\n* Enough time for at least 4 weeks of prehabilitation\n* Screened positive for at least 1 risky SNAP factor\n* Signed informed consent\n\nExclusion Criteria:\n\n* Ventral hernia repairs with defect larger than 8 cm\n* Pregnancy\u002Fbreastfeeding\n* Allergy\u002Fother contradiction to pharmaceutical and\u002For nutritional support\n* Contradiction to exercise\n* Previous complicated alcohol withdrawal symptoms (delirium or seizures)\n* Not able to participate in intervention due to psychiatric ilness",{"count":293,"type":23},400,[26],"The five risky lifestyles Smoking, Nutrition (obesity and malnutrition), risky Alcohol intake, and Physical inactivity (SNAP) are common in surgical patients and associated with worse postoperative outcomes. Mono-factor interventions targeting and improving these risky lifestyles have been shown to reduce the risk at surgery, but there is a lack of systematic assessment of all five lifestyles of the patient before surgery and related optimization.\n\nThis study aims to evaluate the effect of intensive combined lifestyle interventions (the STRONG programme) compared with treatment as usual in patients undergoing ventral hernia repair on postoperative complications, health, and costs on short and longer term.\n\nThe hypothesis is that the STRONG programme will halve the complication rates within 30 days.",[297,298,30,299,300,301],"Ventral Hernia","Surgery","Lifestyle","Postoperative Complications","Prehabilitation",[297,298,30,300,301,303,304,305,306,307],"Smoking","Alcohol drinking","Obesity","Malnutrition","Physical Inactivity","2024-09-20",{"date":310,"type":40},"2024-09-25",{"date":312,"type":40},"2024-03-04",{"date":314,"type":23},"2028-03-01",{"name":316,"class":47},"Bispebjerg Hospital",3,{"id":319,"slug":320,"hasResults":11,"nctId":321,"briefTitle":322,"officialTitle":323,"acronym":324,"eligibilityCriteria":325,"healthyVolunteers":17,"sex":18,"minAge":326,"maxAge":327,"enrollmentInfo":328,"targetDuration":4,"studyType":24,"phases":329,"briefSummary":330,"conditions":331,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":334,"lastUpdatePostDateStruct":335,"startDateStruct":337,"completionDateStruct":339,"leadSponsor":341,"locationsCount":48},"100462078","validation-of-the-reminder-dementia-risk-reduction-program-100462078","NCT05296980","Validation of the REMINDER Dementia Risk Reduction Program","Validation of a Multidomain Neuropsychological Intervention for Individuals at Risk of Dementia: the REMINDER Program","REMINDER","Inclusion Criteria:\n\n* Age 60 or older\n* CAIDE dementia risk score \\>8\n* Cognitive function: absence of significant cognitive impairment as per the Addenbrooke's Cognitive Examination-REVISED\n* Free of physical disabilities that preclude participation in the study\n* Willing to complete all study-related activities for 12 weeks\n\nExclusion Criteria:\n\n* Mild cognitive impairment or dementia;\n* Presence of any neurological event in their medical history that could compromise actual cognition.\n* Presence of any severe psychiatric disorder (mild depressive and anxiety symptoms meet inclusion criteria).\n* Unability to travel to the site where the sessions will be delivered (if so randomization will be circumscribed between the experimental harm REMINDER online and the control group.\n* Illiteracy","60 Years","75 Years",{"count":293,"type":23},[26],"Until now, neuropsychological interventions aimed to optimize cognitive function and to have functional impact in individuals at risk of AD (MCI patients) were scarce in validity studies. While some RCTs have been developed in cognitive training interventions, comparative studies of merged interventions (cognitive, social and behavioral stimulation) with adequate control groups are absent, diminishing the professionals' trust on the adoption of these interventions for supporting patients. As such, the present proposal will develop a validation trial testing a multicomponent neuropsychological intervention (REMINDER), based on personal development, cognitive compensatory aids, meaningful goals setting, and behavior change techniques. The investigators will analyze its short\u002Flong-term gains and AD conversion rates. By aiming to provide a good validation study for REMINDER, the investigators will examine neurobiological, neurocognitive and functional outcomes of this intervention in comparison with an active control group (psychoeducation) in order to foster an effective outcome assessment of an intervention for individuals at risk of AD.",[332,30,333],"Healthy Aging","Old Age; Dementia","2024-05-07",{"date":336,"type":40},"2024-05-08",{"date":338,"type":40},"2022-04-01",{"date":340,"type":23},"2026-10",{"name":342,"class":47},"University of Coimbra",{"id":344,"slug":345,"hasResults":11,"nctId":346,"briefTitle":347,"officialTitle":347,"acronym":4,"eligibilityCriteria":348,"healthyVolunteers":11,"sex":349,"minAge":19,"maxAge":350,"enrollmentInfo":351,"targetDuration":4,"studyType":24,"phases":353,"briefSummary":354,"conditions":355,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":357,"lastUpdatePostDateStruct":358,"startDateStruct":360,"completionDateStruct":362,"leadSponsor":364,"locationsCount":48},"100385105","achievement-and-adherence-to-behavioral-health-goals-in-the-setting-of-patient-directed-goal-choice-100385105","NCT04294381","Achievement and Adherence to Behavioral Health Goals in the Setting of Patient-Directed Goal Choice","Inclusion Criteria:\n\n* females age 18-90\n* who fall into one of the following categories:\n\n  * undergone cardiovascular event (myocardial infarction, percutaneous coronary intervention, or stroke,) or\n  * who have an active cardiac symptom (e.g. chest pain or arrhythmia) or\n  * have three or more active risk factors (i.e. diabetes, hypertension, hyperlipidemia, peripheral artery disease, current smoker, family history of premature coronary disease, gestational diabetes, pregnancy-induced hypertension\u002Fpre-eclampsia, or obesity).\n\nExclusion Criteria:\n\n* pregnancy\n* type 1 diabetes\n* a psychiatric diagnosis that precludes participation\n* dementia\n* under the care of another multi-disciplinary clinic.","FEMALE","90 Years",{"count":352,"type":23},50,[26],"Health care decisions should include patients' health outcome goals and care preferences so as to enable a unified set of individualized patient outcome goals, rather than disparate disease-specific goals that do not reflect patient choice and commitment. This study utilizes a skilled professional interview and a simple tablet-based tool to enable patient choice of health behavior goals. The tool guides the patient to choose a specific, measurable, attainable, realistic and time-based (SMART) goal. The hypothesis of this study is that the implementation this patient choice tool will increase the likelihood of patient adherence to the goal and increase patient self efficacy.",[356,30],"Sedentary Behavior","2023-04-23",{"date":359,"type":40},"2023-04-25",{"date":361,"type":40},"2020-09-01",{"date":363,"type":23},"2026-06-30",{"name":365,"class":47},"Hadassah Medical Organization"]